| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/25/2012 | EP2408452A1 Compound for the treatment of tuberculosis |
| 01/25/2012 | EP2408434A1 Treating alzheimer's disease and osteoporosis and reducing aging |
| 01/25/2012 | EP2040754B1 Use of adipose-tissue cell fractions for post-irradiation tissue regeneration |
| 01/25/2012 | EP1879591B1 Use of azapaullones for preventing and treating pancreatic autoimmune disorders |
| 01/25/2012 | EP1773314B1 Use of l-carnitine for the treatment of cardiovascular diseases |
| 01/25/2012 | EP1725245B1 Manganese and iron based compounds for elastogenesis and connective tissue treatment |
| 01/25/2012 | EP1685849B1 Pde 4 inhibitors for the treatment of interstitial cystitis |
| 01/25/2012 | EP1550462B1 Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| 01/25/2012 | EP1434597B1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 01/25/2012 | EP1351707B9 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 01/25/2012 | CN1981872B Use of PUMA in tumor chemoradiotherapy sensibilization |
| 01/25/2012 | CN1897890B Use of alginate matrices to control cell growth |
| 01/25/2012 | CN1558759B 病毒聚合酶抑制剂 Viral polymerase inhibitors |
| 01/25/2012 | CN102333759A Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| 01/25/2012 | CN102333546A Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin |
| 01/25/2012 | CN102333545A Enhanced migraine treatments based on ghrelin mimetics |
| 01/25/2012 | CN102333543A Cell adhesion inhibitor and use thereof |
| 01/25/2012 | CN102327614A Combinations comprising dipeptidylpeptidase - iv inhibitor |
| 01/25/2012 | CN102327613A Application of ErbB receptor stimulant to preparation of medicament for treating epilepsy |
| 01/25/2012 | CN102327601A Hemostat for resisting infection and promoting wound healing and preparation method thereof |
| 01/25/2012 | CN102327285A Formulations decreasing infectivity of pulmonary diseases |
| 01/25/2012 | CN102327211A Pharmaceutical manufacturing process for heat sterilized glucocorticoid suspensions |
| 01/25/2012 | CN101695483B Independently controllable contraceptive transdermal patch containing progestogen and estrogen and preparation method thereof |
| 01/25/2012 | CN101495147B Pharmaceutical combinations. |
| 01/24/2012 | US8101793 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 01/24/2012 | US8101659 Methods of treatment and pharmaceutical composition |
| 01/24/2012 | US8101652 For therapy of neoplastic diseases |
| 01/24/2012 | US8101650 Method for treating a immunology-related disease |
| 01/24/2012 | US8101635 Use of glutamate antagonists which is a NMDA receptor antagonist ( ifenprodil, memantine) to reduce or control retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy ( vision defect ) |
| 01/24/2012 | US8101599 Pharmaceutical composition containing anti-hypertensive agents |
| 01/24/2012 | US8101370 Genes from the 20q13 amplicon and their uses |
| 01/24/2012 | US8101363 Obtaining a level of a marker of systemic inflammation in individual, comparing level of marker to a predetermined value specific for diagnosis of diabetes or diabetic complications, and characterizing the individual's risk profile |
| 01/24/2012 | US8101188 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 01/24/2012 | US8101181 Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| 01/24/2012 | US8101176 Compositions and methods related to TIM-3, a TH1-specific cell surface molecule |
| 01/24/2012 | US8101163 Transdermal compositions |
| 01/24/2012 | US8101160 Formulations for use in inhaler devices |
| 01/24/2012 | CA2499902C Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person |
| 01/24/2012 | CA2455227C Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 01/24/2012 | CA2383174C Method of treating cardio pulmonary diseases with no group compounds |
| 01/24/2012 | CA2344317C Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke |
| 01/24/2012 | CA2332370C Methods and means for preventing or treating inflammation or pruritis |
| 01/24/2012 | CA2269204C Anti-erbb2 antibodies |
| 01/24/2012 | CA2221730C Use of angiotensin ii type 2 receptor agonists in tissue repair |
| 01/19/2012 | WO2012008507A1 Therapeutic agent for cancer |
| 01/19/2012 | WO2012008395A1 Substrate of three-layer structure and water-containing adhesive patch including same |
| 01/19/2012 | WO2012007729A2 Pharmaceutical compositions |
| 01/19/2012 | WO2012007560A1 Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue |
| 01/19/2012 | WO2012007159A2 Novel gastro-retentive dosage forms |
| 01/19/2012 | WO2012006967A1 Poly(ethylene oxide) and base surfactant in suppository composition |
| 01/19/2012 | WO2010140007A9 Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug |
| 01/19/2012 | US20120016467 Polymer-based, sustained release drug delivery system |
| 01/19/2012 | US20120016035 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 01/19/2012 | US20120015917 Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy |
| 01/19/2012 | US20120015024 Methods for treating tweak-related conditions |
| 01/19/2012 | US20120014965 Compositions and methods of treating tumors |
| 01/19/2012 | US20120014948 Genetic products differentially expressed in tumors and use thereof |
| 01/19/2012 | US20120014916 Polyalkylene polymer compounds and uses thereof |
| 01/19/2012 | US20120014907 Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases |
| 01/19/2012 | CA2805700A1 Pharmaceutical compositions |
| 01/19/2012 | CA2804969A1 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system |
| 01/19/2012 | CA2803242A1 Backing having three-layer structure and aqueous patch using the backing |
| 01/18/2012 | EP2407786A1 Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer |
| 01/18/2012 | EP2407556A1 Method for determining sensitivity to irinotecan and use thereof |
| 01/18/2012 | EP2407473A2 Method for producing phosphorus-containing compounds |
| 01/18/2012 | EP2407179A1 External preparation containing analgesic/anti-inflammatory agent |
| 01/18/2012 | EP2406304A1 Gaba-linked anthracycline-lipid conjugates |
| 01/18/2012 | EP2405941A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| 01/18/2012 | EP2405755A1 Methods and compositions for the treatment of metabolic and cardiovascular disorders |
| 01/18/2012 | EP2405750A1 Combination therapy with thiocolchicine derivatives |
| 01/18/2012 | EP2405747A1 Compositions and methods for treatment and prevention of cardiovascular disease |
| 01/18/2012 | EP1950294B1 Novel cell penetrating peptide |
| 01/18/2012 | EP1826197B1 Aminocarboxylic acid derivative and medicinal use thereof |
| 01/18/2012 | EP1713471B1 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 01/18/2012 | EP1637539B1 Pyrazole derivative, drug composition containing the same and production intermediate therefor |
| 01/18/2012 | EP1494730B1 Composition for hard tissue augmentation |
| 01/18/2012 | EP1490024B1 Effervescent compositions comprising alendronate |
| 01/18/2012 | EP1392849B2 Yeast screens for agents affecting protein folding |
| 01/18/2012 | EP1390075B1 Chemotherapeutic induction of egr-1 promoter activity in gene therapy |
| 01/18/2012 | EP1360957B1 Vitamin/mineral complex |
| 01/18/2012 | EP1341528B1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 01/18/2012 | EP1292709B1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 01/18/2012 | EP1123388B1 Transgenic c. elegans as a model organism for research into alzheimer's disease |
| 01/18/2012 | CN102325905A Method for determining sensitivity to irinotecan and use thereof |
| 01/18/2012 | CN102321626A Means for inhibiting the expression of protein kinase 3 |
| 01/18/2012 | CN102321572A Method for purifying and recognizing pancreatic endocrine cells |
| 01/18/2012 | CN102319439A Drug with magnetic microspheres, and use thereof |
| 01/18/2012 | CN102319433A Combinations of a pyrimidine containing nnrti with rt inhibitors |
| 01/18/2012 | CN102319432A Ocular implant made by a double extrusion process |
| 01/18/2012 | CN102319421A Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 01/18/2012 | CN102319409A Antimicrobial compositons containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 01/18/2012 | CN102319231A Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 01/18/2012 | CN101522195B Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent |
| 01/18/2012 | CN101491670B Method for treating cardiovascular disease using nervous regulation protein and composite |
| 01/17/2012 | US8097648 Methods and compositions for use in treating cancer |
| 01/17/2012 | US8097647 Augmented cognitive training |
| 01/17/2012 | US8097625 Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 01/17/2012 | US8097607 loading-dose regimen; an initial administration of rifalazil for 4 to 14 days, followed by less than half this average daily dose for the subsequent 4 to 14 days |
| 01/17/2012 | US8097605 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease |
| 01/17/2012 | US8097600 Method of increasing tear production with purinergic receptor agonists |